Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVIENT CORPPOL · Entity 4061 | SVP & President DSS | February 15, 2017 | February 17, 2017 |
| Danimer Scientific, Inc.DNMR · Entity 83400 | Director · Interim CEO | October 14, 2024 | October 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVIENT CORP
Report date February 15, 2017 · Filed February 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2020-02-15 | Direct | 4,150 |
Reported balance
After 2017-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-15 · Grant · Acquired 4,150 · Balance 4,150 F1: Each restricted stock unit represents a contingent right to receive one share of PolyOne common stock. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $34.10 · Expires 2027-02-15 | Direct | 12,450 |
Reported balance
After 2017-02-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-02-15 · Grant · Acquired 12,450 · Balance 12,450 F2: SARs become exercisable and vest only upon the achievement of both price and time requirements. To vest, each one-third of the grant must attain 10%, 15% and 20% stock appreciation, respectively (which must be maintained for a minimum of thirty consecutive trading days) from the grant date closing price of $34.10 per share and no more than one-third of the grant can vest per year during the first three years. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of PolyOne common stock.
F2: SARs become exercisable and vest only upon the achievement of both price and time requirements. To vest, each one-third of the grant must attain 10%, 15% and 20% stock appreciation, respectively (which must be maintained for a minimum of thirty consecutive trading days) from the grant date closing price of $34.10 per share and no more than one-third of the grant can vest per year during the first three years.
Danimer Scientific, Inc.
Report date October 14, 2024 · Filed October 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $0.55 · Expires 2034-10-14 | Direct | 300,000 |
Reported balance
After 2024-10-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-10-14 · Grant · Acquired 300,000 · Balance 300,000 F1: These stock appreciation rights (SARs) to purchase shares of the Issuer's Class A common stock ("Common Stock") were granted to Reporting Person on October 14, 2024 under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (the "Plan"). SARs to purchase 300,000 shares of the Issuer's Common Stock will vest and become exercisable on October 14, 2025 subject to recipient's continued service as a director of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: These stock appreciation rights (SARs) to purchase shares of the Issuer's Class A common stock ("Common Stock") were granted to Reporting Person on October 14, 2024 under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (the "Plan"). SARs to purchase 300,000 shares of the Issuer's Common Stock will vest and become exercisable on October 14, 2025 subject to recipient's continued service as a director of the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 14, 2024 Filed Oct 16, 2024 16:30 UTC | Danimer Scientific, Inc. DNMR · Entity 83400 | GrantStock Appreciation Rights · Derivative | 300,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0000950170-24-115021 · ownership.xml · derivative · entry 1 Altice Richard N. · CIK 0001539629 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-10-14 F1 · derivative.exercise_date: These stock appreciation rights (SARs) to purchase shares of the Issuer's Class A common stock ("Common Stock") were granted to Reporting Person on October 14, 2024 under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (the "Plan"). SARs to purchase 300,000 shares of the Issuer's Common Stock will vest and become exercisable on October 14, 2025 subject to recipient's continued service as a director of the Company. Read SEC document |
| July 18, 2024 Filed Jul 22, 2024 09:25 UTC | Danimer Scientific, Inc. DNMR · Entity 83400 | GrantRestricted Stock Units · Derivative | 86,957 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-085080 · ownership.xml · derivative · entry 1 Altice Richard N. · CIK 0001539629 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,957 Underlying: Common Stock · 86,957 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Danimer Scientific Class A common stock. F2 · derivative.exercise_date: Comprised of an award of restricted stock units (RSU) granted as director compensation under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (the "Plan") with each RSU representing the right to receive one share of Danimer Scientific Class A Common Stock. All of these RSU's will vest and become non-forfeitable on July 9, 2025 subject to recipient's continued service as a director of the Company. F2 · derivative.expiration_date: Comprised of an award of restricted stock units (RSU) granted as director compensation under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (the "Plan") with each RSU representing the right to receive one share of Danimer Scientific Class A Common Stock. All of these RSU's will vest and become non-forfeitable on July 9, 2025 subject to recipient's continued service as a director of the Company. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 16:00 UTC | Danimer Scientific, Inc. DNMR · Entity 83400 | GrantRestricted Stock Units · Derivative | 8,242 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-045087 · ownership.xml · derivative · entry 1 Altice Richard N. · CIK 0001539629 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,242 Underlying: Common Stock · 8,242 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Danimer Scientific Class A common stock. F2 · derivative.expiration_date: Comprised of an award of restricted stock units (RSU) granted as director compensation under the Danimer Scientific, Inc. 2020 Long-Term Incentive Plan (the "Plan") with each RSU representing the right to receive one share of Danimer Scientific Class A Common Stock. All of these RSU's will vest and become non-forfeitable on April 15, 2025 subject to recipient's continued service as a director of the Company. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 21:46 UTC | AVIENT CORP POL · Entity 4061 | GrantStock Appreciation Rights · Derivative | 12,450 | $0.00 Strike: $34.10 | $0.00 |
DisclosureSEC source: 0001127602-17-006963 · form4.xml · derivative · entry 2 Altice Richard N. · CIK 0001539629 · SVP & President DSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,450 Underlying: Common Stock · 12,450 shares Expires 2027-02-15 F2 · derivative.exercise_date: SARs become exercisable and vest only upon the achievement of both price and time requirements. To vest, each one-third of the grant must attain 10%, 15% and 20% stock appreciation, respectively (which must be maintained for a minimum of thirty consecutive trading days) from the grant date closing price of $34.10 per share and no more than one-third of the grant can vest per year during the first three years. Read SEC document |
| February 15, 2017 Filed Feb 17, 2017 21:46 UTC | AVIENT CORP POL · Entity 4061 | GrantRestricted Stock Units · Derivative | 4,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-006963 · form4.xml · derivative · entry 1 Altice Richard N. · CIK 0001539629 · SVP & President DSS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,150 Underlying: Common Stock · 4,150 shares Expires 2020-02-15 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of PolyOne common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.